[go: up one dir, main page]

MX2018005977A - Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico. - Google Patents

Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.

Info

Publication number
MX2018005977A
MX2018005977A MX2018005977A MX2018005977A MX2018005977A MX 2018005977 A MX2018005977 A MX 2018005977A MX 2018005977 A MX2018005977 A MX 2018005977A MX 2018005977 A MX2018005977 A MX 2018005977A MX 2018005977 A MX2018005977 A MX 2018005977A
Authority
MX
Mexico
Prior art keywords
anticholinergic
corticosteroid
dry powder
powder formulation
adrenergic
Prior art date
Application number
MX2018005977A
Other languages
English (en)
Other versions
MX379853B (es
Inventor
Schiaretti Francesca
Cafiero Claudio
Ortenzi Leonardo
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018005977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2018005977A publication Critical patent/MX2018005977A/es
Publication of MX379853B publication Critical patent/MX379853B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La invención se relaciona con una formulación en polvo seco para inhalación que comprende una combinación de un anticolinérgico, un agonista de beta2-adrenoceptor de acción prolongada, y un corticosteroide, y con un proceso para la preparación de la misma.
MX2018005977A 2015-11-16 2016-11-14 Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico. MX379853B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16
PCT/EP2016/077558 WO2017085004A1 (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Publications (2)

Publication Number Publication Date
MX2018005977A true MX2018005977A (es) 2018-08-29
MX379853B MX379853B (es) 2025-03-11

Family

ID=54548062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005977A MX379853B (es) 2015-11-16 2016-11-14 Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.

Country Status (35)

Country Link
US (4) US10086004B2 (es)
EP (3) EP3620176B1 (es)
JP (1) JP6963548B2 (es)
KR (1) KR20180082443A (es)
CN (1) CN108289962B (es)
AR (1) AR106688A1 (es)
AU (1) AU2016356858B2 (es)
CL (1) CL2018001298A1 (es)
CO (1) CO2018005141A2 (es)
CY (3) CY1123042T1 (es)
DK (3) DK3377108T3 (es)
EA (1) EA037716B1 (es)
ES (3) ES2895687T3 (es)
GE (2) GEP20207157B (es)
HR (3) HRP20211600T1 (es)
HU (3) HUE056441T2 (es)
IL (1) IL259329B (es)
LT (3) LT3377108T (es)
MA (3) MA50487B1 (es)
MD (3) MD3620176T2 (es)
ME (1) ME03778B (es)
MX (1) MX379853B (es)
MY (1) MY186229A (es)
PE (1) PE20181488A1 (es)
PH (1) PH12018501022A1 (es)
PL (3) PL3628331T3 (es)
PT (3) PT3628331T (es)
RS (3) RS62506B1 (es)
SA (1) SA518391570B1 (es)
SG (2) SG10201912093YA (es)
SI (3) SI3377108T1 (es)
TW (1) TWI731891B (es)
UA (1) UA125019C2 (es)
WO (1) WO2017085004A1 (es)
ZA (1) ZA201803168B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350164B2 (en) 2017-05-11 2019-07-16 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
EP3947338A4 (en) * 2019-03-27 2023-01-04 Kemin Industries, Inc. METHODS FOR PREPARING METAL CARBOXYLATES IN A MONOTOPE REACTION
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12178782B2 (en) * 2021-03-24 2024-12-31 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
EP1658872B2 (en) 2002-07-31 2019-08-21 CHIESI FARMACEUTICI S.p.A. Powder inhaler
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
CA2803418A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
WO2014086927A1 (en) * 2012-12-06 2014-06-12 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
GEP20186839B (en) * 2012-12-06 2018-04-10 Chiesi Farma Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
ES2699986T3 (es) * 2013-07-11 2019-02-13 Chiesi Farm Spa Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación

Also Published As

Publication number Publication date
MA50488A (fr) 2021-05-19
MA50487B1 (fr) 2021-09-30
MA50487A (fr) 2021-04-28
ES2783855T3 (es) 2020-09-18
SI3620176T1 (sl) 2021-11-30
CO2018005141A2 (es) 2018-09-28
HUE049751T2 (hu) 2020-10-28
US10086004B2 (en) 2018-10-02
EP3620176B1 (en) 2021-08-11
RS62506B1 (sr) 2021-11-30
EP3377108B1 (en) 2020-02-19
UA125019C2 (uk) 2021-12-29
EP3628331A1 (en) 2020-04-01
SI3377108T1 (sl) 2020-05-29
RS62404B1 (sr) 2021-10-29
AU2016356858B2 (en) 2021-06-24
BR112018009807A2 (pt) 2018-11-06
SI3628331T1 (sl) 2021-11-30
PL3377108T3 (pl) 2020-09-07
CY1123042T1 (el) 2021-10-29
ES2891073T3 (es) 2022-01-26
ME03778B (me) 2021-04-20
US20170136035A1 (en) 2017-05-18
IL259329A (en) 2018-07-31
MD3628331T2 (ro) 2021-12-31
RS60171B1 (sr) 2020-05-29
PH12018501022B1 (en) 2018-12-17
ES2895687T3 (es) 2022-02-22
MA50488B1 (fr) 2021-09-30
AU2016356858A1 (en) 2018-05-31
PL3628331T3 (pl) 2021-11-08
EP3377108A1 (en) 2018-09-26
NZ742474A (en) 2024-11-29
EP3620176A1 (en) 2020-03-11
GEAP202014783A (en) 2020-04-27
DK3620176T3 (da) 2021-09-20
SA518391570B1 (ar) 2022-03-27
PH12018501022A1 (en) 2018-12-17
HUE056441T2 (hu) 2022-02-28
MY186229A (en) 2021-06-30
PL3620176T3 (pl) 2021-11-22
SG10201912093YA (en) 2020-02-27
CL2018001298A1 (es) 2018-09-14
MD3377108T2 (ro) 2020-07-31
MX379853B (es) 2025-03-11
EP3628331B1 (en) 2021-08-11
US20180360849A1 (en) 2018-12-20
LT3628331T (lt) 2021-11-10
DK3628331T3 (da) 2021-09-27
TWI731891B (zh) 2021-07-01
WO2017085004A1 (en) 2017-05-26
ZA201803168B (en) 2019-07-31
SG11201804050QA (en) 2018-06-28
HRP20200537T1 (hr) 2020-06-26
PT3620176T (pt) 2021-09-28
IL259329B (en) 2020-10-29
PT3628331T (pt) 2021-10-20
HRP20211600T1 (hr) 2022-01-21
JP2019501876A (ja) 2019-01-24
CY1124490T1 (el) 2022-07-22
PE20181488A1 (es) 2018-09-18
US20200368252A1 (en) 2020-11-26
GEP20207157B (en) 2020-10-12
HUE056260T2 (hu) 2022-02-28
CA3005290A1 (en) 2017-05-26
MA43256A (fr) 2018-09-26
CY1124475T1 (el) 2022-07-22
MA43256B1 (fr) 2020-05-29
US20210177866A1 (en) 2021-06-17
EA037716B1 (ru) 2021-05-13
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
JP6963548B2 (ja) 2021-11-10
US11628175B2 (en) 2023-04-18
CN108289962B (zh) 2021-09-14
AR106688A1 (es) 2018-02-07
BR112018009807A8 (pt) 2019-02-26
US10966991B2 (en) 2021-04-06
LT3377108T (lt) 2020-07-10
US10772896B2 (en) 2020-09-15
PT3377108T (pt) 2020-04-08
TW201722404A (zh) 2017-07-01
KR20180082443A (ko) 2018-07-18
HRP20211598T1 (hr) 2022-01-07
EA201890966A1 (ru) 2018-11-30
CN108289962A (zh) 2018-07-17
DK3377108T3 (da) 2020-04-20

Similar Documents

Publication Publication Date Title
CO2018005141A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
CO2018005139A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
TH1601000099A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด